Fundacion Ibis Para la Investigacion de HIV/SIDA

ROR: 01462bm80

OpenAlex ID: I4405258730

Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators

2019 · Loveleen Bansi-Matharu, Gabriela Rodriguez Loria, et al. · AIDS · 10

Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America

2018 · Yanink Caro-Vega, Anna Schultze, et al. · BMC Infectious Diseases · 9

Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D 2 EFT

2022 · Emmanuelle Papot, Simone Jacoby, et al. · HIV Research & Clinical Practice · 7

Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

2023 · David M. MacDonald, Sarah Samorodnitsky, et al. · Scientific Reports · 3

MoCA Utility as a Quick Testing Tool for Neurocognitive Disorders in HIV Patients: Analysis of a Prospective Cohort

2017 · Vanina Stanek, Marisa Del Luján Sanchez, et al. · Open Forum Infectious Diseases · 3

A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study

2025 · Phyo Pyae Nyein, Margaret Borok, et al. · Clinical Infectious Diseases · 2

Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial

2026 · Jason V Baker, Lianne K Siegel, et al. · Clinical Infectious Diseases · 1

SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

2024 · Emmanuelle Papot, Tamara Tovar-Sanchez, et al. · AIDS

Works count: 8

Citation count: 62